Notícias e Atividades da Cyclacel Pharmaceuticals
Executivos
Veja o organograma con seus 7 executivos principais
Biografias mais buscadas da Cyclacel Pharmaceuticals
- Wong Sing Ee, Chief Executive Officer and Executive Director
- Christopher Henney, Chairman of the Board
- Kenneth Ferguson, Director
Recentes movimentos de executivos em Cyclacel Pharmaceuticals
- Wong Sing Ee, ingressou na Companhia como Chief Executive Officer and Executive Director (Notícia publicada em 2 de março de 2025).
- Kiu Cu Seng, ingressou na Companhia como Executive Director, Secretary and Chief Financial Officer (Notícia publicada em 2 de março de 2025).
- Samuel Barker, Director, deixou a Companhia (Notícia publicada em 2 de março de 2025).
Criar um alerta
para seguir os movimentos de executivos da Cyclacel Pharmaceuticals.
Farmacêutica
Cyclacel Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
- Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado em 12 de março de 2025).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Cyclacel Pharmaceuticals
- Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results | Cyclacel Pharmaceuticals, Inc.
- RSS News Feeds | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING | Cyclacel Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Cyclacel Pharmaceuticals
- Cyclacel Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Cyclacel Pharmaceuticals na LinkedIn, Twitter e YouTube
